Comparison of Peripheral and Central Schizophrenia Biomarker Profiles

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Harris, Laura W ^a   Pietsch, Sandra ^a   Cheng, Tammy M K ^a   Schwarz, Emanuel ^a   Guest, Paul C ^a   Bahn, Sabine ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA;

ADULT; ARTICLE; AUTOPSY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MALE; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADULT; AUTOPSY; BIOLOGICAL MARKERS; BRAIN; CENTRAL NERVOUS SYSTEM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM; SCHIZOPHRENIA;

EID: 84868112176     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046368     Document Type: Article

References (41)

1. Hafner H, Maurer K, (2006) Early detection of schizophrenia: current evidence and future perspectives. World Psychiatry 5: 130-138.
2. Knapp M, Mangalore R, Simon J, (2004) The global costs of schizophrenia. Schizophr Bull 30: 279-293.
3. Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, et al. (2012) Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 17: 494-502.
4. Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, et al. (2011) Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 36: 1092-1096.
5. Messamore E, Hoffman WF, Janowsky A, (2003) The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study. Schizophr Res 62: 251-258.
6. Curtis CE, Iacono WG, Beiser M, (1999) Relationship between nailfold plexus visibility and clinical, neuropsychological, and brain structural measures in schizophrenia. Biol Psychiatry 46: 102-109.
7. Schiffman J, Ekstrom M, LaBrie J, Schulsinger F, Sorensen H, et al. (2002) Minor physical anomalies and schizophrenia spectrum disorders: a prospective investigation. Am J Psychiatry 159: 238-243.
8. Schwarz E, Izmailov R, Spain M, Barnes A, Mapes JP, et al. (2010) Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 5: 39-47.
9. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society B 57: 289-300.
10. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, et al. (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9: 684-697, 643.
11. Harris LW, Wayland M, Lan M, Ryan M, Giger T, et al. (2008) The cerebral microvasculature in schizophrenia: a laser capture microdissection study. PLoS One 3: e3964.
12. Ryan MM, Lockstone HE, Huffaker SJ, Wayland MT, Webster MJ, et al. (2006) Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. Mol Psychiatry 11: 965-978.
13. Greenbaum D, Colangelo C, Williams K, Gerstein M, (2003) Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 4: 117.
14. Forster C, Silwedel C, Golenhofen N, Burek M, Kietz S, et al. (2005) Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system. J Physiol 565: 475-486.
15. Soderlund J, Schroder J, Nordin C, Samuelsson M, Walther-Jallow L, et al. (2009) Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry 14: 1069-1071.
16. Schmitt A, Bertsch T, Tost H, Bergmann A, Henning U, et al. (2005) Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatr Dis Treat 1: 171-177.
17. Krishnamurthy D, Levin Y, Harris LW, Umrania Y, Bahn S, et al. (2011) Analysis of the human pituitary proteome by data independent label-free liquid chromatography tandem mass spectrometry. Proteomics 11: 495-500.
18. Kariagina A, Romanenko D, Ren SG, Chesnokova V, (2004) Hypothalamic-pituitary cytokine network. Endocrinology 145: 104-112.
19. Ghigo E, Arvat E, Giordano R, Broglio F, Gianotti L, et al. (2001) Biologic activities of growth hormone secretagogues in humans. Endocrine 14: 87-93.
20. Fitzgerald P, Dinan TG, (2008) Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol 22: 12-19.
21. Phelps CJ, (1994) Pituitary hormones as neurotrophic signals: anomalous hypophysiotrophic neuron differentiation in hypopituitary dwarf mice. Proc Soc Exp Biol Med 206: 6-23.
22. Mielke JG, Wang YT, (2011) Insulin, synaptic function, and opportunities for neuroprotection. Prog Mol Biol Transl Sci 98: 133-186.
23. Huang CC, Lee CC, Hsu KS, (2010) The role of insulin receptor signaling in synaptic plasticity and cognitive function. Chang Gung Med J 33: 115-125.
24. McIntyre RS, Vagic D, Swartz SA, Soczynska JK, Woldeyohannes HO, et al. (2008) Insulin, insulin-like growth factors and incretins: neural homeostatic regulators and treatment opportunities. CNS Drugs 22: 443-453.
25. McIntyre RS, Soczynska JK, Woldeyohannes H, Miranda A, Konarski JZ, (2007) Thiazolidinediones: from antioxidant to neurotherapeutic? Med Hypotheses 69: 773-777.
26. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R, (2007) C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 93: 261-265.
27. Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, et al. (2007) Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 149: 267-271.
28. Yasojima K, Schwab C, McGeer EG, McGeer PL, (2000) Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res 887: 80-89.
29. Avgustin B, Wraber B, Tavcar R, (2005) Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat Med J 46: 268-274.
30. Rothermundt M, Arolt V, Leadbeater J, Peters M, Rudolf S, et al. (2000) Cytokine production in unmedicated and treated schizophrenic patients. Neuroreport 11: 3385-3388.
31. Ramchand R, Wei J, Ramchand CN, Hemmings GP, (1994) Increased serum IgE in schizophrenic patients who responded poorly to neuroleptic treatment. Life Sci 54: 1579-1584.
32. Andoh T, Kuraishi Y, (2004) Expression of Fc epsilon receptor I on primary sensory neurons in mice. Neuroreport 15: 2029-2031.
33. Chen Z, Qiu X, Gu J, (2009) Immunoglobulin expression in non-lymphoid lineage and neoplastic cells. Am J Pathol 174: 1139-1148.
34. Carrizo E, Fernandez V, Quintero J, Connell L, Rodriguez Z, et al. (2008) Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr Res 103: 83-93.
35. Fulzele S, Pillai A, (2009) Decreased VEGF mRNA expression in the dorsolateral prefrontal cortex of schizophrenia subjects. Schizophr Res 115: 372-373.
36. Fleisig H, El-Din El-Husseini A, Vincent SR, (2004) Regulation of ErbB4 phosphorylation and cleavage by a novel histidine acid phosphatase. Neuroscience 127: 91-100.
37. Leake A, Morris CM, Whateley J, (2000) Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease. Neurosci Lett 291: 201-203.
38. Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD, (2007) Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 50: 202-211.
39. Dantz D, Bewersdorf J, Fruehwald-Schultes B, Kern W, Jelkmann W, et al. (2002) Vascular endothelial growth factor: a novel endocrine defensive response to hypoglycemia. J Clin Endocrinol Metab 87: 835-840.
40. Koga M, Otsuki M, Kubo M, Hashimoto J, Kasayama S, (1998) Relationship between circulating vascular cell adhesion molecule-1 and microvascular complications in type 2 diabetes mellitus. Diabet Med 15: 661-667.
41. Peter K, Nawroth P, Conradt C, Nordt T, Weiss T, et al. (1997) Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 17: 505-512.